SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The Breast Cancer Immunotherapy Guideline Expert Panel was formed to generate consensus recommendations pertaining to the treatment of patients with breast cancer. In March 2019, accelerated approval was granted by the U.S. FDA for the checkpoint inhibitor atezolizumab in combination with chemotherapy for the treatment of PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC)—the first immuno-oncology agent approval for this disease setting. Trials are ongoing evaluating other immunotherapeutic agents as monotherapies and combination regimens for the treatment of TNBC and other breast cancer subtypes. Reflecting the evolving therapeutic landscape, SITC is currently developing a breast cancer CPG with topics including selection of appropriate immunotherapeutic regimens, companion diagnostics, recognition and management of adverse events, and patient quality of life considerations.
Published August 13, 2021 in the Journal for ImmunoTherapy of Cancer (JITC) as "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer"
In this introductory webinar, Expert Panel members provide attendees with an overview of the published guideline and highlight selected recommendations that are applicable to some of the most common scenarios clinicians may encounter while treating their patients with immunotherapy. After attending this webinar, learners will be better able to implement immunotherapy treatments effectively and in accordance with the recommendations in the SITC CPG. CME, CNE and CPE credits are available.
This advanced webinar is designed so that attendees will know how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease.This webinar is not accredited.
Jennifer Litton, MDThe University of Texas MD Anderson Cancer Center
Sylvia Adams, MD – New York University Langone Perlmutter Cancer Center
Ashley Cimino-Mathews, MD – Johns Hopkins Hospital
Mary L. Disis, MD, FACP – University of Washington
Margaret E. Gatti-Mays, MD, MPH – The Ohio State University
Alice Y. Ho, MD – Massachusetts General Hospital
Kevin Kalinsky, MD, MS – Emory University
Heather L. McArthur, MD, MPH – UT Southwestern
Elizabeth A. Mittendorf MD, PhD – Dana-Farber Cancer Institute and Brigham & Woman's Cancer Institute
Rita Nanda, MD – University of Chicago
David B. Page, MD – Earle A. Chiles Research Institute
Hope S. Rugo, MD, FASCO – UCSF Helen Diller Family Comprehensive Care Center
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
Hatem Soliman, MD – Moffitt Cancer Center
Patricia Spears (Patient Advocate) – UNC School of Medicine Lineberger Comprehensive Cancer Center
Sara M. Tolaney, MD, MPH – Dana-Farber Cancer Institute
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com